An increased sensitivity of ATRX altered tumour cells to DNA damage response (DDR) inhibitors targeting ATM58, WEE163, ATR and PARP64,65 has been reported in other neuroectodermal cancers, and therefore might be effective in PCPG. This evidence concerns the gene ATRX and neoplasm.